MannKind Corporation has announced that it has received a $12.5 million milestone payment from United Therapeutics for the first milestone related to development of a treprostinil Technosphere (TreT) DPI for the treatment of pulmonary arterial hypertension. The company did not specify what milestone had been achieved.
United Therapeutics and MannKind announced the licensing and collaboration deal, which included a $45 million payment up front, in September 2018. In addition to the $12.5 million first milestone payment, MannKind could be eligible for an additional $37.5 million on the achievement of further milestones, as well as double digit royalties on net sales if the DPI is approved.
In June 2018, MannKind announced that a Phase 1 trial of TreT had met its primary endpoint. That trial appears to be the only study of TreT currently listed in clinicaltrials.gov or the EU Clinical Trials Register.
Read the MannKind Corporation press release.
